Laura Roca-Alonso
Chief Operating Officer en E-THERAPEUTICS PLC .
Perfil
Laura Roca-Alonso is currently the Chief Operating & Business Officer at e-Therapeutics Plc since 2020.
Prior to this, she worked as the VP & Head-Corporate Development at Silence Therapeutics Plc from 2004 to 2019.
She also worked as the Director-Business Development at Gyroscope Therapeutics Ltd.
Dr. Roca-Alonso holds a doctorate degree from Imperial College London, a graduate degree from University College London, and an undergraduate degree from Autonomous University of Barcelona.
Cargos activos de Laura Roca-Alonso
| Empresas | Cargo | Inicio |
|---|---|---|
| E-THERAPEUTICS PLC | Chief Operating Officer | 02/04/2020 |
Antiguos cargos conocidos de Laura Roca-Alonso.
| Empresas | Cargo | Fin |
|---|---|---|
| SILENCE THERAPEUTICS PLC | Corporate Officer/Principal | 01/01/2019 |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Corporate Officer/Principal | - |
Formación de Laura Roca-Alonso.
| Imperial College London | Doctorate Degree |
| University College London | Graduate Degree |
| Autonomous University of Barcelona | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| E-THERAPEUTICS PLC | Health Technology |
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Empresas privadas | 1 |
|---|---|
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Laura Roca-Alonso
